ARCTURUS THERAPEUTICS HOLDINGS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -1.90% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-03
- ARCTURUS THERAPEUTICS HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -1.90%.
- ARCTURUS THERAPEUTICS HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -2.50%, a 115.53% decline from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was 16.10%.
- ARCTURUS THERAPEUTICS HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was -0.40%, a 107.27% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2024-12-31 | -1.90% 10-K · filed 2026-03-03 |
| 2023-12-31 | -2.50% 10-K · filed 2026-03-03 |
| 2022-12-31 | 16.10% 10-K · filed 2025-03-06 |
| 2021-12-31 | -0.40% 10-K · filed 2024-03-14 |
| 2020-12-31 | 5.50% 10-K · filed 2022-03-01 |
| 2019-12-31 | -0.10% 10-K · filed 2022-03-01 |
| 2018-12-31 | -0.20% 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |